BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27783335)

  • 1. BRCA1 allele-specific expression in genetic predisposed breast/ovarian cancer.
    Jamard E; Volard B; Dugué AE; Legros A; Leconte A; Clarisse B; Davy G; Polycarpe F; Dugast C; Abadie C; Frebourg T; Tinat J; Tennevet I; Layet V; Joly F; Castéra L; Berthet P; Vaur D; Krieger S
    Fam Cancer; 2017 Apr; 16(2):167-171. PubMed ID: 27783335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of
    Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
    J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.
    Takahashi M; Chiba N; Shimodaira H; Yoshino Y; Mori T; Sumii M; Nomizu T; Ishioka C
    Breast Cancer; 2017 Mar; 24(2):336-340. PubMed ID: 27271530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.
    Pajares B; Porta J; Porta JM; Sousa CF; Moreno I; Porta D; Durán G; Vega T; Ortiz I; Muriel C; Alba E; Márquez A
    BMC Cancer; 2018 Jun; 18(1):647. PubMed ID: 29884136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. copy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer.
    Kuusisto KM; Akinrinade O; Vihinen M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    PLoS One; 2013; 8(8):e71802. PubMed ID: 23967248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    Cao WM; Zheng YB; Gao Y; Ding XW; Sun Y; Huang Y; Lou CJ; Pan ZW; Peng G; Wang XJ
    BMC Cancer; 2019 Jun; 19(1):551. PubMed ID: 31174498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
    Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
    J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    Ryu JM; Nam SJ; Kim SW; Lee JE; Chae BJ; Lee SK; Yu J
    Jpn J Clin Oncol; 2020 Feb; 50(2):104-113. PubMed ID: 31926487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.